Elevance Health 3Q 2025 Earnings Presentation October 21, 2025 -- 1 of 15 -- 2 Key Highlights Elevance Health third quarter operational results consistent with expectations • Benefit expense ratio of 91.3% in line with revised outlook • Adjusted diluted EPS1 of $6.03 reflects ~$1 of higher net investment income and timing of certain tax benefits • Reaffirm full year adjusted diluted EPS1 guidance of ~$30, including a benefit expense ratio of ~90.0% and ~$3 of discrete, non-core items 3Q 2025 Results & 2025 Outlook1 Providing insight into key planning assumptions; earnings guidance to be set in January: • Disciplined positioning across Medicare Advantage, Commercial, and Individual ACA businesses • Medicaid operating margin expected to decline by at least 125 basis points year-over-year, as rate increases lag acuity and utilization trends • Medicare Advantage membership impacted by approximately 150k members from service area and plan exits; 2026 bids prioritize pricing discipline and sustainable margin profile • Carelon expected to deliver continued strong growth across both Pharmacy and Health Services; results will be impacted by Health Benefits membership trends, with the full impact assessed in January • Several hundred million dollars of incremental investments to scale Carelon, advance our AI and digital strategy, and improve Star ratings • 2026 investments and Carelon expansion position Elevance Health for balanced earnings growth in 2027 2026 Considerations 2 • Scaling our enterprise flywheel through Carelon’s differentiated value-based care solutions • Demonstrating steady improvement in Star ratings performance, with ~55% of Medicare Advantage members in 4-Star or higher contracts for payment year 2027, up from ~40%; three contracts achieved a 5-Star rating • Expanding digital innovation such as HealthOS, AI-enabled clinical support, and our digital virtual assistant to increase access to care, reduce costs, and create greater efficiency • Deploying capital opportunistically, with a near-term focus on share repurchases Strategic Focus Areas3 1. See “GAAP Reconciliation” on slides 12 and 13 herein. -- 2 of 15 -- 33 Key Highlights • Elevance Health third quarter results reflect solid execution as we focus on the levers within our control to deliver sustainable, long-term performance • Operating revenue of $50.1B grew 12.0%, due to higher premium yields in Health Benefits, recently closed acquisitions, and Medicare Advantage membership growth, partly offset by Medicaid reverifications • Benefit expense ratio of 91.3% consistent with expectations and reflecting elevated cost trend across lines of business • Adjusted operating expense ratio of 10.4% includes targeted strategic investments while maintaining cost discipline • Operating cash flow of $1.1B impacted by BCBSA Provider Settlement Agreement payment 3Q 2025 Results Change (%/bps) 3Q 2024 3Q 2025 Elevance Health 12.0% $44.7B $50.1B Operating Revenue 1 180 bps 89.5% 91.3% Benefit Expense Ratio 100 bps 9.4% 10.4% Adjusted Operating Expense Ratio1,2 (45.3%) $2.5B $1.3B Adjusted Operating Gain1,2 (280) bps 5.5% 2.7% Adjusted Operating Margin 1,2 13.4% $551M $625M Net Investment Income (29.9%) $8.60 $6.03 Adjusted Diluted EPS 2 ($1.5B) $2.7B $1.1B Operating Cash Flow 1. See “Basis of Presentation” on slide 11 herein. 2. See “GAAP Reconciliation” on slides 12 and 13 herein. -- 3 of 15 -- 44 Key Highlights • Health Benefits results were consistent with expectations; reflect incremental investments to support our long-term performance • Operating revenue grew 10.4% year over year, driven by higher premium yields, recently closed acquisitions, and growth in Medicare Advantage membership, partly offset by Medicaid reverifications • Adjusted operating margin of 1.4% declined by 280 bps due to elevated, but anticipated, medical cost trends and incremental investments to support our workforce and accelerate technology adoption • Membership of 45.4M reflects lower BlueCard membership and ongoing Medicaid reverifications, offset by targeted growth and higher retention rates in Medicare Advantage Change (%/bps) 3Q 2024 3Q 2025 Health Benefits 10.4% $38.3B $42.2B Operating Revenue 1 (63.0%) $1.6B $0.6B Adjusted Operating Gain1,2 (280) bps 4.2% 1.4% Adjusted Operating Margin 1,2 (0.9%) 45.8M 45.4M Membership 1. See “Basis of Presentation” on slide 11 herein. 2. See “Reportable Segment Highlight Details” on slide 14 herein. Health Benefits 3Q 2025 Results -- 4 of 15 -- 55 Key Highlights • Carelon’s results driven by strength of our integrated platform and continued execution across Pharmacy and Services, with investments to sustain growth • CarelonRx operating revenue grew ~20% driven by momentum with large clients and recent specialty pharmacy acquisitions; operating margin reflects planned integration and technology investments to support growth • Carelon Services revenue up ~60% supported by CareBridge integration and expansion of risk-based and home- health capabilities; operating margin reflects expected seasonality and continued scaling of the platform 3Q 2025 Results Change (%/bps) 3Q 2024 3Q 2025 Carelon 32.9% $13.8B $18.3B Operating Revenue 1 (9.5%) $0.9B $0.8B Adjusted Operating Gain1,2 (200) bps 6.2% 4.2% Adjusted Operating Margin 1,2 6.0% 80.2M 85.0M Adjusted Scripts (3.7%) 101.3M 97.6M Consumers Served 1. See “Basis of Presentation” on slide 11 herein. 2. See “Reportable Segment Highlight Details” on slide 14 herein. Health Services -- 5 of 15 -- 66 Elevance Health is a Lifetime, Trusted Health Partner Lowering the cost of healthcare We anticipate health trends early, give caregivers the tools they need, and make care easier to afford. Making healthcare simple We make accessing and using healthcare easy, cutting red tape and simplifying systems and processes so providers can provide care, and members can live their healthiest lives. To deliver on our mission of improving lives and communities and simplifying healthcare WHAT HOW WHY A lifetime, trusted health partner committed to making healthcare better…better costs, better experience, better outcomes – for your whole health. -- 6 of 15 -- 77 Flywheel Supports Our Long-Term Growth Algorithm Health Benefits Optimize the Core Invest in Growth Accelerate Targeting at least 12% average annual growth in Adjusted Diluted Earnings Per Share Over 45M medical members balanced across commercial, Medicaid, Medicare, and the Federal Employee Program, leveraging the assets and capabilities of Carelon to accelerate growth As an integrated portfolio of whole health solutions serving approximately 100M consumers, Carelon connects care across physical, behavioral, social, home health, and pharmacy needs to bend the cost curve, enhance consumer experiences, and deliver whole health, affordably Health Services -- 7 of 15 -- 88 Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1 Long-Term Growth Algorithm Revenue Growth High Single Digit CAGR1 Adjusted Operating Margin Expanding to 6.5% - 7.0% Capital Deployment Approximately 4% Contribution to Adjusted Diluted EPS CAGR 1 Health Benefits Mid to High Single Digit CAGR Driven by membership growth, cost trend, geographic expansion, and growth in specialized populations Carelon Services High Teens to Low Twenties CAGR Driven by risk-based revenue growth including M&A CarelonRx Low Double Digit CAGR Driven by script volumes and drug mix Transforming our business processes by leveraging new technologies across operations Commitment to operating efficiency and optimizing core businesses Effective medical management Underwriting discipline Share Repurchases Organic Reinvestment Programmatic M&A targeting integrated solutions that strengthen health plan competitiveness + + Targeting at least 12% average annual growth in Adjusted Diluted EPS 1. CAGR = Compound Annual Growth Rate Target. -- 8 of 15 -- 99 Committed to Strong Growth Over the Long-Term M&A/ Organic Reinvestment 50% Share Repurchase 30% Dividends 20% 5.3% 6.5% – 7.0% 2024 Target $175B High Single Digit CAGR1 2024 Target Elevance Health 5.8% Mid to High Single Digit 2024 Target $54B Mid Teens CAGR1 2024 Target Carelon 2 4.2% 5.5% – 6.5% 2024 Target $150B Mid to High Single Digit CAGR1 2024 Target Health Benefits Capital Allocation Targeting at least 12% average annual growth in Adjusted Diluted EPS Adjusted 3 Operating Margin Revenue (in billions) 1. CAGR = Compound Annual Growth Rate Target. 2. The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) a high teens to low twenties revenue CAGR and mid to high single digit operating margin for Carelon Services. 3. See “GAAP Reconciliation” on slides 12 and 13 herein. -- 9 of 15 -- 10 Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations. -- 10 of 15 -- 11 Non-GAAP Measures and Basis of Presentation This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available on Slides 12-13 of this document. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. -- 11 of 15 -- 12 12 Elevance Health GAAP Reconciliation — Shareholders’ Net Income and Shareholders’ Earnings Per Diluted Share Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2024 2025 Change 2024 2025 (In millions, except per share data) (8.0)% $5,562 $5,115 17.0% $1,016 $1,189 Shareholders' net income Add / (Subtract): 400 464 122 162 Amortization of other intangible assets 158 182 42 49 Transaction and integration related costs1 680 19 669 4 Litigation and settlement expenses1 371 596 125 1 Net losses on financial instruments 191 — 72 — Business dispositions and related items 2 (201) — 39 — (Gain) loss on sale of business 268 (4) 268 (4) Business optimization charges 1 (482) (307) (348) (52) Tax impact of non-GAAP adjustments 1,385 950 989 160 Net adjustment items (12.7)% $6,947 $6,065 (32.7)% $2,005 $1,349 Adjusted shareholders' net income (4.8)% $23.81 $22.67 22.0% $4.36 $5.32 Shareholders’ earnings per diluted share Add / (Subtract): 1.71 2.06 0.52 0.72 Amortization of other intangible assets 0.68 0.81 0.18 0.22 Transaction and integration related costs1 2.91 0.08 2.87 0.02 Litigation and settlement expenses1 1.59 2.64 0.54 — Net losses on financial instruments 0.82 — 0.31 — Business dispositions and related items 2 (0.86) — 0.17 — (Gain) loss on sale of business 1.15 (0.02) 1.15 (0.02) Business optimization charges 1 (2.06) (1.36) (1.49) (0.23) Tax impact of non-GAAP adjustments 5.93 4.21 4.24 0.71 Net adjustment items (9.6)% $29.74 $26.88 (29.9)% $8.60 $6.03 Adjusted shareholders’ earnings per diluted share Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2024 2025 Change 2024 2025 (In millions) (11.0)% $7,298 $6,495 2.4% $1,373 $1,406 Income before income tax expense (1,524) (1,701) (551) (625) Net investment income (201) — 39 — (Gain) loss on sale of business 371 596 125 1 Net losses on financial instruments 845 1,036 300 351 Interest expense 400 464 122 162 Amortization of other intangible assets (4.2)% $7,189 $6,890 (8.0)% $1,408 $1,295 Reportable segments operating gain 1. Adjustment item resides in the Corporate & Other reportable segment. 2. Adjustment item resides in the Health Benefits and Carelon Services reportable segments. 3. Totals may not foot due to rounding. -- 12 of 15 -- 13 13 Elevance Health GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and 2025 Outlook Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2024 2025 Change 2024 2025 (In millions) 2.3% $15,221 $15,569 0.1% $5,269 $5,272 Operating expense Add / (Subtract): (158) (182) (42) (49) Transaction and integration related costs1 (680) (19) (669) (4) Litigation and settlement expenses1 (191) — (72) — Business dispositions and related items 2 (268) 4 (268) 4 Business optimization charges 1 (1,297) (197) (1,051) (49) Net adjustment items 10.4% $13,924 $15,372 23.8% $4,218 $5,223 Adjusted operating expense 13.9% $130,215 $148,273 12.0% $44,719 $50,087 Operating revenue (120) bp 11.7% 10.5% (130) bp 11.8% 10.5% Operating expense ratio (30) bp 10.7% 10.4% 100 bp 9.4% 10.4% Adjusted operating expense ratio Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2024 2025 Change 2024 2025 (In millions) (4.2)% $7,189 $6,890 (8.0)% $1,408 $1,295 Reportable segments operating gain Add / (Subtract): 158 182 42 49 Transaction and integration related costs1 680 19 669 4 Litigation and settlement expenses1 191 — 72 — Business dispositions and related items 2 268 (4) 268 (4) Business optimization charges 1 1,297 197 1,051 49 Net adjustment Items (16.5)% $8,486 $7,087 (45.3)% $2,459 $1,344 Reportable segments adjusted operating gain Full Year 2025 Outlook Approximately $24.70 Shareholders’ earnings per diluted share Add / (Subtract): $2.98 Amortization of other intangible assets3 $2.90 Net losses on financial instruments3 $1.03 Transaction and integration related costs1, 3 $0.10 Litigation and settlement expenses1, 3 ($0.02) Business optimization charges 1 Approximately ($1.69) Tax impact of non-GAAP adjustments3 $5.30 Net adjustment items Approximately $30.00 Adjusted shareholders’ earnings per diluted share 1. Adjustment item resides in the Corporate & Other reportable segment. 2. Adjustment item resides in the Health Benefits and Carelon Services reportable segments. 3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount. -- 13 of 15 -- 14 14 Elevance Health Reportable Segment & Health Benefits Revenue Details Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2024 2025 Change 2024 2025 (In millions, Unaudited) Operating Revenue 11.1% $112,695 $125,259 10.4% $38,278 $42,246 Health Benefits 22.2% 25,984 31,756 20.3% 9,143 10,997 CarelonRx 61.5% 13,192 21,301 57.9% 4,638 7,324 Carelon Services 69.0% 323 546 101.4% 74 149 Corporate & Other NM 6 (21,979) (30,589) NM 6 (7,414) (10,629) Eliminations 13.9% $130,215 $148,273 12.0% $44,719 $50,087 Total Operating Revenue1 Operating Gain (Loss) (27.5)% $6,036 $4,378 (62.5)% $1,604 $601 Health Benefits 2 3.4% 1,639 1,694 (10.2)% 619 556 CarelonRx 62.8% 682 1,110 19.0% 184 219 Carelon Services2 NM 6 (1,168) (292) NM 6 (999) (81) Corporate & Other 2,3 (4.2)% $7,189 $6,890 (8.0)% $1,408 $1,295 Total Operating Gain1,4 Operating Margin (190) bp 5.4% 3.5% (280) bp 4.2% 1.4% Health Benefits (100) bp 6.3% 5.3% (170) bp 6.8% 5.1% CarelonRx — bp 5.2% 5.2% (100) bp 4.0% 3.0% Carelon Services (90) bp 5.5% 4.6% (50) bp 3.1% 2.6% Total Operating Margin1 1. See “Basis of Presentation” on slide 11 herein. 2. Operating Gain for the three and nine months ended September 30, 2024, included $72 and $191 million, respectively, of 2024 business dispositions and related items; including $53 and $141 million, respectively, for the Carelon Services segment; and $19 and $50 million, respectively, for the Health Benefits segment. Operating Gain for the three and nine months ended September 30, 2024, included $42 and $158 million, respectively, of transaction and integration related costs, $669 and $680 million, respectively, of litigation and settlement expenses, and $268 and $268 million, respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment. 3. Operating Gain for the three and nine months ended September 30, 2025, included $49 and $182 million, respectively, of transaction and integration related costs, $4 and $19 million, respectively, of litigation and settlement expenses, and ($4) and ($4), respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment. 4. Operating Gain for the three and nine months ended September 30, 2025, and September 30, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on slides 12 and 13 herein. 5. The Individual business, including ACA products, is reported as part of Commercial Operating Revenue. 6. "NM" = calculation not meaningful. Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not allocated to our other reportable segments). Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2024 2025 Change 2024 2025 (In millions, Unaudited) Health Benefits Operating Revenue 7.7% $34,965 $37,654 10.4% $11,639 $12,849 Commercial 14.1% 6,178 7,047 13.3% 2,082 2,358 Individual 5 22.5% 27,741 33,990 18.7% 9,385 11,138 Medicare 7.5% 39,182 42,120 8.4% 13,063 14,166 Medicaid 6.4% 10,807 11,495 (2.3)% 4,191 4,093 Federal Employee Program 11.1% $112,695 $125,259 10.4% $38,278 $42,246 Total Health Benefits Operating Revenue1 -- 14 of 15 -- -- 15 of 15 --